Biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) said on Monday that it will form a joint venture entity, called HaloVax, to commence preclinical studies for the development of the COVID-19 vaccine in partnership with Voltron Therapeutics Inc.
The JV HaloVax will begin the preclinical studies for the development of vaccine prospects to prevent COVID-19 based upon VaxCelerate, a self-assembling vaccine (SAV) platform, which was exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Under the joint agreement, Hoth and Voltron and MGH will explore and develop this SAV technology to aid patients at risk of being infected with COVID-19. The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology has demonstrated proof of concept in Lassa Fever, an emerging infectious disease.
In conjunction, HaloVax plans to use the same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic. VaxCelerate offers two unique elements to combat the Coronavirus - one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.
This proposed vaccine reportedly focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack, added the partnership.
As part the agreement, Hoth will receive the right to receive single digit royalties from the sale of any products developed and shall have the right to acquire up to a 30% equity interest in HaloVax.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial